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Razoxane (Razoxin), has been reported to have
antimetastatic, antitumour and radiosensitising
activities in pre-clinical models. Clinical evidence of
therapeutic value in combination with radiotherapy
is, however, tenuous.
This study was designed to provide evidence of
therapeutic efficacy of razoxane as an antitumour
or radiosensitising agent in the palliative treatment
of locally advanced bronchial carcinoma.
Patients with untreated non-small cell or
unknown histology and no clinical evidence of
metastatic disease, referred to the Department of
Radiotherapy in Birmingham for palliative radio-
therapy after January 31, 1980 were eligible. Those
patients with evidence of pleural effusion or distant
metastases and those who had received previous
radiotherapy or chemotherapy were not eligible.
Baseline assessments included history, physical,
performance status, chest X-ray, haematology and
liver function tests. Other investigations were
performed when indicated on clinical grounds. The
design of this trial, which was double-blind, placebo
controlled and utilised sequential analysis, has been
previously described (Jones et al., 1982). Prospective
randomisation was achieved using the variance
method ofFreedman & White (1976) which balanced
for the stratification factors histology, history of
previous surgery and performance status.
Razoxane 125mg orally twice daily was started 3
days before, and continued during radiotherapy.
After radiotherapy razoxane was continued on 5
days each week at the discretion of the physician in
charge. No direct assessment of patient compliance
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was made. The protocol was later modified, based
on the reported experience of others to allow
discontinuation of therapy if the white cell count
was <2000 x 1091- . Placebo tablets, indistinguish-
able from razoxane, were administered in an
identical way. Radiotherapy was given with
palliative intent and was usually 3000-3500cGy in
10-15 fractions over 2-3 weeks. Field sizes, to
include tumour mass and mediastinum, were
usually 12cm x 15cm. Patients were followed
monthly for 3 months and 3 monthly thereafter by
study staff.
The sequential design involved a comparison of
the survival experiences of the two groups, using
log rank analysis after every 12 deaths. The design
was constructed so that significance (at the 5%
level, one-sided alternative) would be observed with
probability 0.9 if the hazard on razoxane was 0.8 of
that on placebo.
The inspections required by the sequential design
showed from the first that the razoxane group was
experiencing the poorer survival. This was contrary
to expectation. Fortunately, the sequential design
picked up this inferiority quickly and enabled the
trial to be terminated after only 8 inspections. At
this time 148 patients had been treated, 102 had
died and 1 patient was lost to follow-up. Median
survival time in the razoxane group was 80 days
and in the placebo group it was 175 days.
Because the trial was terminated as a result of
the observed inferiority of razoxane, a standard log
rank analysis is not valid. The appropriate analysis
(Whitehead et al., 1983) estimates the hazard ratio
(razoxane: placebo) to be 1.76 with a 95%
confidence interval of (1.16, 2.83). Razoxane was
significantly inferior to placebo (P<0.05, two-sided
alternative). The life table analysis of survival in
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each group at the termination of the study is shown
in Figure 1. Further details of the method of
analysis are given in Section 5.3 of Whitehead
(1983).
Preliminary analysis of the data indicates that
study groups are balanced with respect to
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Figure 1 Cumulative proportions surviving (Kaplan-
Meyer estimates).
Total no. still at
risk beyond 0 100 200 300 400 600 800 d
Placebo 74 41 26 21 9 4 1
Razoxane 74 27 15 11 1 1 0
stratification factors (age, sex...). Performance
status was the only statistically significant
stratification factor for survival. There was no
interaction between these factors and treatment.
The unequivocal difference in survival experience
merits reporting of this preliminary analysis and the
conclusions that razoxane is of no benefit and is
significantly worse than placebo.
Myelosuppression and depression of humoral
immunity in mice, have been described with
razoxane. Although leucopaenia is more common
in the razoxane group, initial analysis in this study
does not indicate the cause of the adverse effect of
razoxane.
We are aware of reports of 2 previous double-
blind, placebo-controlled trials of razoxane
combined with radiotherapy by Bakowski et al.
(1978) and Belloni et al. (1983). One reported no
benefit in operable cervical cancer, the other
reported deletrious effects in head and neck cancer.
This short communication describes the third such
study and is the second to report detrimental effects
when razoxane and radiation therapy are combined.
We should like to thank our radiotherapy colleagues in
the Queen Elizabeth, Dudley Road and General
Hospitals, Birmingham, for referring their patients to the
study.
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